Oncotarget

Reviews:

Long non-coding RNA in glioma: signaling pathways

Jia Shi, Bo Dong, Jiachao Cao, Yumin Mao, Wei Guan, Ya Peng and Suinuan Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:27582-27592. https://doi.org/10.18632/oncotarget.15175

Metrics: PDF 1902 views  |   HTML 2448 views  |   ?  


Abstract

Jia Shi1,*, Bo Dong1,*, Jiachao Cao1,*, Yumin Mao1, Wei Guan1, Ya Peng1 and Suinuan Wang1

1 Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China

* These authors have contributed equally to this work

Correspondence to:

Suinuan Wang, email:

Ya Peng, email:

Keywords: long non-coding RNAs, glioma, microRNA

Received: November 11, 2016 Accepted: January 24, 2017 Published: February 07, 2017

Abstract

Glioma is regarded as the most prevalent malignant carcinoma of the central nervous system. Thus, the development of new therapeutic strategies targeting glioma is of significant clinical importance. Long non-coding RNAs (lncRNAs) are functional RNA molecules without a protein-coding function and are reportedly involved in the initiation and progression of glioma. Dysregulation of lncRNAs in glioma is due to activation of several signaling pathways, such as the BRD4-HOTAIR-β-catenin/PDCD4, p53-Hif-H19/IGF2 and CRNDE/mTOR pathways. Furthermore, microRNAs (miRNAs) such as miR-675 also interact with lncRNAs in glioma. Thus, exploring the mechanisms by which lncRNA control processes will be instrumental for devising new effective therapies against glioma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15175